| BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., May 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |
| BrightSpring mischt einen Milliardenmarkt auf | Auf den ersten Blick ist das Geschäft von BrightSpring margenschwach und wenig attraktiv. Doch gerade das eröffnet enorme Chancen für Skalierung und Konsolidierung Den vollständigen Artikel lesen ... ► Artikel lesen |
| BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita | LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and... ► Artikel lesen |
| BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen |
| BillionToOne, Inc.: BillionToOne Provides Guidance for 2026 | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen |
| BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen |
| Alpha Tau Medical Ltd.: Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting | - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of... ► Artikel lesen |
| Alpha Tau Medical Ltd.: Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update | - Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of... ► Artikel lesen |
| Alpha Tau Medical Ltd.: Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT to Treat Recurrent Cutaneous Squamous Cell Carcinoma | - First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated... ► Artikel lesen |